Key takeaways from FDA's draft guidance on use of AI in drug and biological life cycle

Retrieved on: 2025-01-23 23:54:42

Tags for this article:

Cybernetics

Clinical research

Computational neuroscience

Artificial intelligence

Data science

Applications of artificial intelligence

Pharmacovigilance

Food and Drug Administration

Clinical trial

Medical device

Credibility

Regulation of artificial intelligence

u.s. food and drug administration

Click the tags to see associated articles and topics

Key takeaways from FDA's draft guidance on use of AI in drug and biological life cycle. View article details on hiswai:

Excerpt

Using AI in pharmaceutical manufacturing; Using model-informed drug development that incorporates AI; Using AI in a study using real-world data to ...

Article found on: www.dlapiper.com

View Original Article